Provectus Biopharmaceuticals Inc (PVCT) financial statements (2020 and earlier)

Company profile

Business Address 10025 INVESTMENT DRIVE
KNOXVILLE, TN 37932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1001141716
Cash and cash equivalents1001141716
Receivables0      
Prepaid expense000    
Other current assets   001 
Other undisclosed current assets 10011 
Total current assets:1112151916
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000000
Intangible assets, net (including goodwill)0122344
Intangible assets, net (excluding goodwill)0122344
Other noncurrent assets    000
Other undisclosed noncurrent assets  1133 
Total noncurrent assets:0124674
TOTAL ASSETS:1236202620
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2442410
Accounts payable1332200
Accrued liabilities111000 
Interest and dividends payable0      
Settlement liabilities    2 
Debt1      
Other undisclosed current liabilities      0
Total current liabilities:3442411
Noncurrent Liabilities
Long-term debt and lease obligation1314     
Long-term debt, excluding current maturities1314     
Operating lease, liability0
Liabilities, other than long-term debt11     
Due to related parties11     
Other undisclosed noncurrent liabilities819  013
Total noncurrent liabilities:23159  013
Total liabilities:26191324113
Stockholders' equity
Stockholders' equity attributable to parent(24)(17)(10)316257
Preferred stock   0  0
Common stock0000000
Additional paid in capital209209208208197181153
Accumulated other comprehensive loss(0)      
Accumulated deficit(234)(227)(219)(205)(181)(156)(146)
Total stockholders' equity:(24)(17)(10)316257
TOTAL LIABILITIES AND EQUITY:1236202620

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(6)(8)(14)(25)(25)(13)(13)
Operating loss:(6)(8)(14)(25)(25)(13)(13)
Nonoperating income
(Investment Income, Nonoperating)
0000000
Interest and debt expense(1)(1)     
Loss from continuing operations before equity method investments, income taxes:(8)(9)(14)(25)(25)(13)(13)
Other undisclosed income from continuing operations before income taxes11     
Loss from continuing operations before income taxes:(7)(8)(14)(25)(25)(13)(13)
Income tax benefit22     
Net loss:(5)(6)(14)(25)(25)(13)(13)
Other undisclosed net income (loss) attributable to parent(2)(2)0002(15)
Net loss attributable to parent:(7)(8)(14)(24)(25)(10)(28)
Other undisclosed net loss available to common stockholders, basic  (0)(4)  (1)
Net loss available to common stockholders, diluted:(7)(8)(14)(29)(25)(10)(29)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(5)(6)(14)(25)(25)(13)(13)
Other comprehensive loss(0)      
Comprehensive loss:(5)(6)(14)(25)(25)(13)(13)
Other undisclosed comprehensive loss, net of tax, attributable to parent(2)      
Comprehensive loss, net of tax, attributable to parent:(7)(6)(14)(25)(25)(13)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: